tbuckley/cabot-search huggingface dataset:
MNGO-06EXAMINATION OF THE RELATIONSHIP OF MENINGIOMA VOLUME AND MEASURES OF PROLIFERATION AND VASCULARITY
Authors: Randy Jensen
Journal: Neuro-Oncology (2015)

BACKGROUND: The natural history of surgically treated intracranial meningiomas can be quite variable. Recurrence and patient outcome cannot currently be predicted with accuracy. We explore the correlation of volumetric tumor measurement on preoperative imaging with measures of proliferation and angiogenesis. METHODS: We examined preoperative imaging and tissue from 263 patients with an average follow-up 90 months. Tumor size was obtained by two methods. The first by estimation using measures of maximal diameter in three planes and multiply these measure using the formula length X width X height X 0.5. The second method was by volumetric measures using OSRIX software. Tissue was examined for measures proliferation (MIB-1); and three methods of computer assisted measures of microvascular density (MVD) using antibodies for Factor VIII, CD 31 and CD 105. RESULTS: There is high correlation between tumor volume measured by the cross sectional diameter measures and volumetric measures. Both are positively correlated with MIB-1 measurement (p = 0.011). In a similar manner, higher tumor volumes are associated with higher MVD measures (p = 0.037). We also found a correlation between the three methods of MVD measurements but comparison of the accuracy of methods still needs to be examined. Progression-free survival (PFS) was associated with higher grade (p < 0.001), MIB-labeling index (p < 0.001) on pairwise comparisons. Using multivariate analysis, PFS was associated with MIB-labeling index (HR 1.68, p = 0.005). Shorter overall survival was associated with MIB-labeling index (HR 1.87, p < 0.001) when controlled for age. CONCLUSION: MIB-1 and MVD measures correlate with tumor volume measured by a two methods. With further refinement these molecular markers may be used to predict outcome for patients with intracranial meningiomas.
Bezlotoxumab — A New Agent for<i>Clostridium difficile</i>Infection
Authors: John G. Bartlett
Journal: New England Journal of Medicine (2017)

Clostridium difficile was identified in 1976 as the cause of "clindamycin colitis" in a study of the hamster model of the disease. That work led to the identification of toxin A ("cytotoxin") and toxin B ("enterotoxin"), oral vancomycin for treatment, and the problem of relapsing disease.1C. difficile infection has subsequently become a major health problem in the United States and much of the world, fueled in part by the global epidemic of the NAP-1 strain (ribotype 027). However, the extensive use and abuse of antibiotics are also implicated, especially the often unnecessary use of fluoroquinolones and second-generation and third-generation . . .
Detailed Phenotypic Characterization of T-Cell Populations in Reactive, Normal and Follicular Lymphoma Nodes: Elevation of Follicular B Helper T-Cell Subsets in Follicular Lymphoma.
Authors: Shannon P. Hilchey, Shelley Secor-Socha, Matthew R. Cochran, Ollivier Hyrien, W. Richard Burack, Jyh-Chiang E. Wang, Sally A. Quataert, Steven H. Bernstein
Journal: Blood (2009)
The Clinical Use of Donor-Derived Virus-Specific Cytotoxic T Lymphocytes Reactive Against Cytomegalovirus (CMV), Adenovirus and Epstein Barr Virus (EBV).
Authors: Doug Myers, Ann M. Leen, Ulahan Sili, Mary H. Huls, Elizabeth Buza, Kathy Leung, George Carrum, Robert A. Krance, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop, Catherine M. Bollard
Journal: Blood (2005)
A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil®) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide
Authors: Tomer M Mark, Adriana C Rossi, Roger N Pearse, Morton Coleman, David Bernstein, Faiza Zafar, Usama Gergis, Tsiporah B. Shore, Ruben Niesvizky
Journal: Blood (2010)
A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).
Authors: David Kuter, James B. Bussel, Louis M. Aledort, James George, Roger M. Lyons, George T. Conklin, Alan E. Lichtin, Jorge Nieva, Reggie Kelly, Chien-Feng Chen, Janet L. Nichol
Journal: Blood (2004)
Response to Dasatinib in Patients with Aggressive Systemic Mastocytosis with D816V Kit Mutation.
Authors: Michela Rondoni, Stefania Paolini, Sabrina Colarossi, Pier Paolo Piccaluga, Cristina Papayannidis, Francesca Palandri, Claudio Laterza, Francesco De Rosa, Patrizia Pregno, Simona Gatto, Emanuela Ottaviani, Giuseppe Saglio, Daniela Cilloni, Fabrizio Pane, Massimo Triggiani, Simona Soverini, Alfonso Zaccaria, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2007)
Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
Authors: Jennifer S. Lee, Po-Yin Chang, Ying Zhang, Jorge R. Kizer, Lyle G. Best, Barbara V. Howard
Journal: Diabetes Care (2017)

High triglyceride (TG) levels and low HDL cholesterol (HDL-C) levels are risk factors for cardiovascular disease. It is unclear whether this relationship depends on glycemic dysregulation, sex, or LDL cholesterol (LDL-C) level.We studied 3,216 participants (40% men, 41% with diabetes) who were free of cardiovascular disease at baseline in a community-based, prospective cohort of American Indians (median follow-up 17.7 years). Cox models estimated hazard ratios (HRs) and 95% CIs for incident ischemic stroke and coronary heart disease (CHD) in relation to combined TG and HDL-C status, where a fasting TG level ≥150 mg/dL was "high" and a fasting HDL-C level <40 mg/dL for men (<50 mg/dL for women) was "low." Models included age, sex, BMI, smoking, diabetes, fasting LDL-C level, antihypertensive medications, physical activity, estimated glomerular filtration rate, and urinary albumin-to-creatinine ratio.Participants with high TG and low HDL levels had a 1.32-fold greater HR (95% CI 1.06-1.64) for CHD than those with normal TG and normal HDL levels. It was observed in participants with diabetes, but not in those without diabetes, that high TG plus low HDL levels were associated with a 1.54-fold greater HR (95% CI 1.15-2.06) for CHD (P value for interaction = 0.003) and a 2.13-fold greater HR (95% CI 1.06-4.29) for stroke (P value for interaction = 0.060). High TG and low HDL level was associated with CHD risk in participants with an LDL-C level of ≥130 mg/dL, but this was not observed in those participants with lower LDL-C levels. Sex did not appear to modify these associations.Adults with both high TG and low HDL-C, particularly those with diabetes, have increased risks of incident CHD and stroke. In particular, those with an LDL-C level ≥130 mg/dL may have an increased risk of incident stroke.
Abstract 8510: Regulation of Microrna-155 of the Atherosclerotic Inflammatory Responses by Targeting Map3k10
Authors: Hui Yan, Ting Chen, Jianhua Zhu, Li Zhang, Zhoubin Li, Lin Yang
Journal: Circulation (2011)

Objectives and Aims: There are increasing evidence that many miRNAs play important roles in cell proliferation, apoptosis and differentiation which accompany immno-inflammatory responses, and as all know that immuno-inflammation is thought to be a major contributor to atherogenesis.This study aims to investigate the potential role of microRNA on the atherosclerosis (AS) immuno-inflammatory mechanism. Methods and results: The miRNA transcriptome was verified by TaqMan Real-time PCR assay with thoracic aorta sample from western-type diet fed APOE knockdown mice and plasma sample from coronary artery disease(CAD)patients.miR-155, miR-146a, miR-9 were aberrantly upregulated in APOE knockdown mice and miR-155, miR-146a, miR-29a were dysregulted in patients with CAD. In particular, miR-155 level was the most significantly elevated both in AS mice and in CAD patients relative to normol control. Moreover, we showed that miR-155 is part of a negative feedback loop, which down-modulates inflammatory cytokine production , lipid uptake and decreases atherosclerosis progression in the oxLDL-treated human monocytic cell line THP-1 and atherosclerotic model mice.(figure) Bioinformatics analysis suggested that mitogen-activated protein kinase kinase kinase 10(MAP3K10) maybe a potential target of miR-155, this was also confirmed by a luciferase reporter assay. Significantly, we suggested an additional explanation for the mechanism of miR-155 mediate immuno-inflammatory response and MAPK pathway by targeting mitogen-activated protein kinase kinase kinase 10. Conclusions: miR-155 contributes to prevent AS development and progression and may be involved in the posttranscriptional regulation of the immno-inflammatory response and MAPK pathway by targeting MAP3K10
Mechanism for leptin’s acute insulin-independent effect to reverse diabetic ketoacidosis
Authors: Rachel J. Perry, Liang Peng, Abudukadier Abulizi, Lynn Kennedy, Gary W. Cline, Gerald I. Shulman
Journal: Journal of Clinical Investigation (2017)

The mechanism by which leptin reverses diabetic ketoacidosis (DKA) is unknown. We examined the acute insulin-independent effects of leptin replacement therapy in a streptozotocin-induced rat model of DKA. Leptin infusion reduced rates of lipolysis, hepatic glucose production (HGP), and hepatic ketogenesis by 50% within 6 hours and were independent of any changes in plasma glucagon concentrations; these effects were abrogated by coinfusion of corticosterone. Treating leptin- and corticosterone-infused rats with an adipose triglyceride lipase inhibitor blocked corticosterone-induced increases in plasma glucose concentrations and rates of HGP and ketogenesis. Similarly, adrenalectomized type 1 diabetic (T1D) rats exhibited decreased rates of lipolysis, HGP, and ketogenesis; these effects were reversed by corticosterone infusion. Leptin-induced decreases in lipolysis, HGP, and ketogenesis in DKA were also nullified by relatively small increases (15 to 70 pM) in plasma insulin concentrations. In contrast, the chronic glucose-lowering effect of leptin in a STZ-induced mouse model of poorly controlled T1D was associated with decreased food intake, reduced plasma glucagon and corticosterone concentrations, and decreased ectopic lipid (triacylglycerol/diacylglycerol) content in liver and muscle. Collectively, these studies demonstrate marked differences in the acute insulin-independent effects by which leptin reverses fasting hyperglycemia and ketoacidosis in a rodent model of DKA versus the chronic pleotropic effects by which leptin reverses hyperglycemia in a non-DKA rodent model of T1D.
Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma
Authors: Saad Usmani, Alan Mitchell, Bijay Nair, Sarah Waheed, Frits van Rhee, Yazan Alsayed, Nathan M Petty, Doug Steward, Susan Panozzo, Antje Hoering, John Crowley, Bart Barlogie
Journal: Blood (2011)
Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?
Authors: Evangelos Terpos, Meletios Athanasios Dimopoulos, Stephanie Harel, Francis K Buadi, Dimitrios Christoulas, Ersi Voskaridou, Efstathios Kastritis, Jean Paul Fermand, Angela Dispenzieri
Journal: Blood (2011)
High-Resolution Analyses of Genetic and Epigenetic Aberrations in Infant Leukemia with MLL Rearrangement.
Authors: Junko Takita, Motohiro Kato, Fumihiko Nakamura, Yuyan Chen, Go Yamamoto, Yasuhito Nannya, Masashi Sanada, Tmohiko Taki, Akira Kikuchi, Takashi Igarashi, Yasuhide Hayashi, Seishi Ogawa
Journal: Blood (2007)
JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression
Authors: Xueqiang Zhao, Yahui Guo, Changying Jiang, Qing Chang, Shilei Zhang, Tianming Luo, Bin Zhang, Xinming Jia, Mien-Chie Hung, Chen Dong, Xin Lin
Journal: Nature Medicine (2017)
The Novel Combination of Sirolimus and Bortezomib Prevents Graft-Versus-Host Disease but Mantains the Graft-Versus-Leukemia Effect After Allogeneic Transplantation.
Authors: Teresa Caballero-Velazquez, Luis Ignacio Sanchez-Abarca, Belen Blanco, Carmen Herrero, Silvia Gutierrez-cosio, Soraya Carrancio, Concepcion Rodriguez-Serrano, Consuelo Cañizo, Jesus F San Miguel, Jose Antonio Perez-Simon
Journal: Blood (2010)
The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib400, Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival
Authors: Franck E Nicolini, Sandrine Hayette, Helene Labussiere, Madeleine Etienne, Marie-Pierre Fort, Elodie Gadolet, Isabelle Tigaud, Kaddour Chabane, Eric Lippert, Mohamad Sobh, Stephanie Dulucq, Stephane Morisset, Mauricette Michallet, Francois-Xavier Mahon, Gabriel Etienne
Journal: Blood (2011)
Acquired Pure Red Cell Aplasia Associated with Alemtuzumab, Mycophenolate, and Daclizumab Immunosuppression after Pancreas Transplant.
Authors: Milena Elimelakh, Vanessa Dayton, Katharine S. Park, Rainer W. Gruessner, Angelika C. Gruessner, David E. Sutherland, Barbara Bland, Robert B. Howe, Jo-Anne van Burik, Aneel A. Asraani, Mark T. Reding, Tim P. Singleton, Nigel S. Key
Journal: Blood (2005)
Current Staging Systems Are Inadequate Predictors of Treatment Failure after Autologous Hematopoietic Stem Cell Transplants (AuHCT) in Multiple Myeloma (MM).
Authors: Parameswaran Hari, Waleska Pérez, Mei-Jie Zhang, Christopher Bredeson, Gustavo Milone, Donna Reece, Vivek Roy, David Vesole
Journal: Blood (2007)
Does Imatinib Change the Outcome in Philapdelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.
Authors: Adele K. Fielding, Susan M. Richards, Hillard M. Lazarus, Mark R. Litzow, Selina M. Luger, David I. Marks, Andrew K. McMillan, Jacob M. Rowe, Martin S. Tallman, Anthony H. Goldstone
Journal: Blood (2007)
Human AML Stem Cells Remain Quiescent and Exhibit Chemotherapy Resistance within the Bone Marrow Endosteal Region.
Authors: Yoriko Saito, Shuro Yoshida, Noriyuki Saito, Mitsuhiro Fukata, Hidetoshi Ozawa, Takehiko Doi, Toshihiro Miyamoto, Koichi Ohshima, Naoyuki Uchida, Shuichi Taniguchi, Koichi Akashi, Mine Harada, Leonard D. Shultz, Fumihiko Ishikawa
Journal: Blood (2007)
Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Authors: Susan M. O'Brien, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan Burger, Kristie Blum, Jeff Sharman, William G. Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd
Journal: Blood (2016)
Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation
Authors: Denise Lau, Linda Yu-Ling Lan, Sarah F. Andrews, Carole Henry, Karla Thatcher Rojas, Karlynn E. Neu, Min Huang, Yunping Huang, Brandon DeKosky, Anna-Karin E. Palm, Gregory C. Ippolito, George Georgiou, Patrick C. Wilson
Journal: Science Immunology (2017)

A distinct population of B cells that respond to vaccination serve as potential plasma cell precursors.
Prospective Qualitative Study Concerning the Efficiency of PBSC Collections after a Change of Apheresis Device
Authors: Marie Y. Detrait, Stephane Morisset, Jean-Pierre Delville, Arnaud Lixon, Julie Boul, Jean-François Colot, Sabine Meurisse, Odile Bocahut, Philippe Mineur, Margareta Nedelcu, Delphine Pranger, Julien Depaus, Carmela Piacentini, Maryvonne Jurdan, Anne Kornreich, Jean-Luc Canon
Journal: Blood (2014)
Three Novel EPAS1/HIF2A Somatic and Germline mutations Associated with Polycythemia and Pheochromocytoma/Paraganglioma.
Authors: Felipe R Lorenzo V, Zhengping Zhuang, Chunzhang Yang, Mark Ng Tang Fui, Hariprasad Vankayalapati, Karel Pacak, Josef T. Prchal
Journal: Blood (2012)
Risk Stratification Using a New Prognostic Model for Patients with Secondary Acute Myeloid Leukemia - Results of the DSIL-AML96 Trial.
Authors: Friedrich Stölzel, Walter E. Aulitzky, Heinrich Bodenstein, Martin Bornhäuser, Michael Kramer, Brigitte Mohr, Uta Oelschlägel, Norbert Schmitz, Silke Soucek, Christian Thiede, Gerhard Ehninger, Markus Schaich
Journal: Blood (2009)
Increased Gene Expression Involved in Angiogenesis, Metabolism and Cell Proliferation in Acute Myeloid Leukemia and myelodysplastic Syndromes Correlates with Adverse Clinical and Biological Features
Authors: Jose F Falantes, Pablo Trujillo, Cristina Calderón, Jose Gonzalez, Maria Luz Martino, Isabel Montero, Rocio Parody, Ildefonso Espigado, Jose Antonio Perez-Simón
Journal: Blood (2012)
Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest
Authors: Susannah L. Rose, Janelle Highland, Matthew T. Karafa, Steven Joffe
Journal: JAMA Internal Medicine (2017)

Patient advocacy organizations (PAOs) are influential health care stakeholders that provide direct counseling and education for patients, engage in policy advocacy, and shape research agendas. Many PAOs report having financial relationships with for-profit industry, yet little is known about the nature of these relationships.To describe the nature of industry funding and partnerships between PAOs and for-profit companies in the United States.A survey was conducted from September 1, 2013, to June 30, 2014, of a nationally representative random sample of 439 PAO leaders, representing 5.6% of 7865 PAOs identified in the United States. Survey questions addressed the nature of their activities, their financial relationships with industry, and the perceived effectiveness of their conflict of interest policies.Amount and sources of revenue as well as organizational experiences with and policies regarding financial conflict of interest.Of the 439 surveys mailed to PAO leaders, 289 (65.8%) were returned with at least 80% of the questions answered. The PAOs varied widely in terms of size, funding, activities, and disease focus. The median total revenue among responding organizations was $299 140 (interquartile range, $70 000-$1 200 000). A total of 165 of 245 PAOs (67.3%) reported receiving industry funding, with 19 of 160 PAOs (11.9%) receiving more than half of their funding from industry. Among the subset of PAOs that received industry funding, the median amount was $50 000 (interquartile range, $15 000-$200 000); the median proportion of industry support derived from the pharmaceutical, device, and/or biotechnology sectors was 45% (interquartile range, 0%-100%). A total of 220 of 269 respondents (81.8%) indicated that conflicts of interest are very or moderately relevant to PAOs, and 94 of 171 (55.0%) believed that their organizations' conflict of interest policies were very good. A total of 22 of 285 PAO leaders (7.7%) perceived pressure to conform their positions to the interests of corporate donors.Patient advocacy organizations engage in wide-ranging health activities. Although most PAOs receive modest funding from industry, a minority receive substantial industry support, raising added concerns about independence. Many respondents report a need to improve their conflict of interest policies to help maintain public trust.
RHAMM (CD168) is overexpressed on the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease
Authors: M. Ringhoffer, M. Hofer, S. Perner, S. Varambally, A. M. Chinnayian, M. A. Rubin, J. Greiner, M. Schmitt, R. Kuefer
Journal: Journal of Clinical Oncology (2007)

5129 Introduction: Treatment options for early stage prostate cancer are well defined, and localized prostate cancer can be cured by several strategies. However therapeutic outcome in advanced tumor stages is still disappointing. One approach is to deliver targeted therapy based on identified human tumor antigens, specifically expressed in neoplastic tissue and recognised by CD4/CD8 T-cells or antibodies. Materials and Methods: We employed serological identification of antigens by recombinant expression cloning (SEREX) and data mining in SEREX related databases to identify potential immunological target structures. Consequently, candidate antigens were screened by DNA microarrays consisting of approximately 20K genes, designed to profile benign and malignant prostate tissues. Genes overexpressed on the cDNA level were evaluated on the protein level by tissue microarrays representing various disease stages including about 900 tissue cores. Protein expression was measured by the Chromavision system. Results: Ten of the targets identified by SEREX and data mining showed a significant overexpression on the 20k cDNA array in localized prostate cancer compared to benign prostatic hyperplasia and in metastases compared to localized prostate cancer. One gene which has been identified earlier as an immunogenic antigen in leukemia by our group, CD168, showed a highly significant overexpression in prostate cancer metastases compared to localized disease (p=0.007). On the protein level CD168 was highest in metastatic tissue samples and significantly higher in neoplastic localized disease compared to benign tissue (p=0.03). High CD168 expression had an association to clinical parameters known to be associated with better clinical outcome. Patients with high CD168 expression in the primaries had a significantly lower risk for biochemical failure (log rank p=0.023; RR:0.621). In cell culture experiments, the number of viable cells was reduced in blocking experiments using hormone sensitive (LNCaP) and hormone insensitive metastatic (PC3 and DU 145) prostate cancer cell lines. Conclusion: Acknowledging the proven immunogenic effects of CD168 in leukemia, this antigen is an intriguing therapeutic target in advanced prostate cancer disease. No significant financial relationships to disclose.
Anticitrullinated protein antibodies: taking into account antibody levels improves interpretation
Authors: Xavier Bossuyt
Journal: Annals of the Rheumatic Diseases (2017)

Hensvold et al 1 reported on the discriminatory capacity of anticitrullinated protein antibodies (ACPA) for diagnosing rheumatoid arthritis (RA).1 A major strength of the study is that it was performed in a population setting and that a large number of controls (n=12 434) were included, thereby allowing a reliable estimate of the specificity of ACPA. The authors give detailed information on the diagnostic performance of anti-CCP2 antibodies (Euro-Diagnostica) for two cut-off points, namely the cut-off point recommended by the manufacturer and a cut-off point that is three times higher than the manufacturer's cut-off point. The latter high cut-off was defined in accordance to the European League against Rheumatism/American College of Rheumatology 2010 RA classification criteria.2 The authors show that the positive likelihood ratio (LR) was higher for the high cut-off (LR=74) than for …
Allelic Expression Imbalance of JAK2 V617F Mutant Contributes to Phenotypic Variation in BCR-ABL Negative Chronic Myeloproliferative Disorders.
Authors: Myung-Geun Shin, Hye-Ran Kim, Hyeoung-Joon Kim, Mi-Ji Kim, Hee-Nam Kim, Yeo-Kyeoung Kim, Soo-Hyun Kim, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang
Journal: Blood (2007)
Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor
Authors: Teresa Field, Janelle Perkins, Taiga Nishihori, Joseph Pidala, Hugo F. Fernandez, Marcie Tomblyn, Mohamed Kharfan-Dabaja, Lia Perez, Jeffrey E. Lancet, Rami S. Komrokji, Jose-Leonel ochoa-Bayona, Melissa Alsina, Ernesto Ayala, Jongphil Kim, Alan F. List, Claudio Anasetti
Journal: Blood (2010)